A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
Clinical trial NCT05055232 · COMPLETED
Trial details
- NCT number
- NCT05055232
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-12
- Primary completion
- 2023-08-15
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.